Valuation: Hologic, Inc.

Capitalization 16.97B 14.49B 13.28B 12.55B 23.24B 1,624B 23.36B 158B 61.55B 771B 63.67B 62.34B 2,679B P/E ratio 2024
24.3x
P/E ratio 2025 27x
Enterprise value 17.39B 14.85B 13.61B 12.86B 23.82B 1,664B 23.94B 162B 63.08B 790B 65.25B 63.88B 2,745B EV / Sales 2024
4.74x
EV / Sales 2025 3.75x
Free-Float
73.08%
Yield 2024 *
-
Yield 2025 -
1 day+0.48%
3 months+1.29%
6 months+2.36%
Current year+2.04%
Current year 74.49
Extreme 74.49
76.07
1 year 53.62
Extreme 53.62
76.07
3 years 51.9
Extreme 51.9
84.67
5 years 51.9
Extreme 51.9
87.88
10 years 26.49
Extreme 26.49
87.88
Manager TitleAgeSince
Chief Executive Officer 63 2026-04-06
Director of Finance/CFO - 2026-04-15
Chief Operating Officer 46 2023-12-31
Director TitleAgeSince
Director/Board Member 63 2026-04-06
Change 5d. change 1-year change 3-years change Capi.($)
+0.48%-.--%+33.07%-8.17% 16.97B
-2.89%-5.69%+3.98%-14.99% 166B
+0.09%-4.31%-23.35%+41.60% 153B
-0.16%-5.11%-15.57%-26.99% 117B
-1.92%-5.25%-48.46%-0.52% 78.87B
+2.08%-2.18%+7.80%-8.74% 46.86B
+1.53%+1.24%-28.66%-37.32% 44.33B
-4.91%-4.18%-6.71%+23.59% 32.89B
-0.14%-4.21%-2.32%-11.57% 31.86B
-0.27%-3.90%-28.78%-45.91% 29.55B
Average -0.62%-3.88%-10.90%-8.90% 71.77B
Weighted average by Cap. -0.90%-4.60%-14.01%-3.45%

Financials

2024 2025
Net sales 4.03B 3.44B 3.15B 2.98B 5.52B 386B 5.55B 37.55B 14.62B 183B 15.12B 14.81B 636B 4.1B 3.5B 3.21B 3.03B 5.62B 392B 5.65B 38.21B 14.87B 186B 15.39B 15.06B 647B
Net income 790M 674M 618M 584M 1.08B 75.56B 1.09B 7.36B 2.86B 35.86B 2.96B 2.9B 125B 566M 483M 443M 418M 775M 54.14B 779M 5.27B 2.05B 25.69B 2.12B 2.08B 89.3B
Net Debt 321M 274M 251M 238M 440M 30.75B 442M 2.99B 1.17B 14.59B 1.21B 1.18B 50.72B 421M 359M 329M 311M 577M 40.28B 580M 3.92B 1.53B 19.12B 1.58B 1.55B 66.44B
Logo Hologic, Inc.
Hologic, Inc. is the world leader in the design, manufacturing and marketing of diagnostic products, medical imaging systems and surgical products dedicated to women's health. Net sales break down by area of application as follows: - breast health (36.2%): digital mammography and breast biopsy solutions and systems; - molecular diagnostics (31.9%): rapid diagnostic tests for human diseases detection (sexually transmitted infections, respiratory diseases, viral diseases, infectious diseases, cancers of the cervix and prostate, etc.) and fetal fibronectin; - gynecological surgery (16.6%): endometrial ablation devices, minimally invasive intervention systems for the hysteroscopic elimination of targeted intrauterine diseases (including fibroids and polyps). The group also offers fluid management systems for use in hysteroscopic procedures; - cytology and perinatal diagnostics (11.9%); - bone health (2.7%): bone imaging systems, bone sonometers and osteodensitometers for bone structure and density, and osteoporotic fractures risk assessment; - blood screening (0.7%). Net sales break down by source of revenue between sales of products (79.4%) and services (20.6%). Net sales are distributed geographically as follows: the United States (74.3%), Europe (14.4%), Asia/Pacific (6%) and other (5.3%).
Employees
7,070
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
AA